Given the significant toxicological risks associated with MAOIs, they are often considered only when other antidepressants are ineffective. Alternatives include selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which generally have a more favorable safety profile. However, MAOIs may still be beneficial for treatment-resistant depression or atypical depression under careful medical supervision.
